Theralase Technologies, Inc. (TLT.V)
0.245
+0.05
(+25.64%)
CAD |
TSXV |
Jan 09, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 62.98M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -19.67% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 60.87 |
| Price to Book Value | 57.65 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.2926 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 72.41% |
Profile
| Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT) segments. The ACT segment covers the research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The CLT segment is responsible for the company’s medical laser business, which researches, develops, manufactures, and distributes CLT systems to healthcare practitioners predominantly for the healing of pain. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada. |
| URL | http://www.theralase.com |
| Investor Relations URL | http://theralase.com/about-us/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT) segments. The ACT segment covers the research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The CLT segment is responsible for the company’s medical laser business, which researches, develops, manufactures, and distributes CLT systems to healthcare practitioners predominantly for the healing of pain. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada. |
| URL | http://www.theralase.com |
| Investor Relations URL | http://theralase.com/about-us/ |
| HQ State/Province | Ontario |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |